NARUMIYA Kosuke    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position
Article types	Original article
Language	English
Peer review	Non peer reviewed
Title	Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: a multi-institutional study.
Journal	Formal name：Esophagus Abbreviation：Esophagus ISSN code：16129067/16129059
Domestic / Foregin	Domestic
Volume, Issue, Page	18(1),pp.65-71
Author and coauthor	Takashi Suzuki, Satoshi Yajima, Akihiko Okamura, Naoya Yoshida, Yusuke Taniyama, Kentaro Murakami, Yu Ohkura, Yasuaki Nakajima, Koichi Yagi, Takashi Fukuda, Ryo Ogawa, Isamu Hoshino, Chikara Kunisaki, Kosuke Narumiya, Yasuhiro Tsubosa, Kazuhiko Yamada, Hideaki Shimada
Publication date	2021/01
Summary	BACKGROUND:Although the clinicopathological significance of serum p53 antibodies (s-p53-Abs) in esophageal cancer have been evaluated previously, previous reports only analyzed around 100-200 patients. This study was a multi-institutional study promoted by the Japan Esophageal Society to evaluate the clinical significance of preoperative s-p53-Ab status and antibody titers in 1487 esophageal cancer patients without neoadjuvant therapy.METHODS:A total of 1487 patients with esophageal squamous cell carcinoma surgically treated between 2008 and 2016 in 15 hospitals in Japan were enrolled. The cut-off value to classify the patients into s-p53-Ab positive and negative groups was 1.30 U/ml. A receiver operating characteristic curve was constructed to assess the s-p53-Abs cut-off levels to differentiate poor prognosis among the s-p53-Ab positive group. Univariate and multivariate analyses were used to evaluate the clinicopathological and prognostic significance of s-p53-Ab status and titers.RESULTS:Although s-p53-Ab status was significantly associated with tumor depth (P = 0.002), nodal status (P = 0.027), and pathological stage (P = 0.002). The s-p53-Ab positive status was not significantly associated with poor overall survival (P = 0.699). Using 9.82 U/ml as a cut-off, the high s-p53-Ab titer group showed a significantly worse overall survival than the low s-p53-Ab titer group (P = 0.038). However, the difference was not significant in the multivariate analysis.CONCLUSION:The presence of s-p53-Abs was associated with tumor progression. Although high s-p53-Ab titers more than 9.82 U/ml, might be associated with poor prognosis for patients with esophageal squamous cell carcinoma, it was not an independent risk factor.
DOI	10.1007/s10388-020-00761-6
PMID	32715348